DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Zevalin (Ibritumomab Tiuxetan) - Side Effect Reports to FDA

 
 



This is an index of side effect / adverse reaction reports (a.k.a. adverse event reports) related to Zevalin (Ibritumomab Tiuxetan) and submitted to the FDA during the sample period of about a year. The information is not vetted and should not be considered as verified clinical evidence.

Reports by Event Outcome

All Cases (58)
Death (21)
Life Threatening Events (1)
Disability (2)

Reports by Reaction Type

White Blood Cell Count Decreased (11)Platelet Count Decreased (11)Myelodysplastic Syndrome (9)Sepsis (8)Neutrophil Count Decreased (7)Anaemia (6)Febrile Neutropenia (6)Neoplasm Malignant (6)Herpes Zoster (5)Pancytopenia (5)Diarrhoea (5)Jaundice (4)

Below are a few examples of reports where side effects / adverse reactions may be related to Zevalin (Ibritumomab Tiuxetan). For a complete list or a specific selection of reports, please use the links above.

Possible Zevalin side effects in

Reported by a consumer/non-health professional from Germany on 2012-08-15

Patient:

Reactions: Haemorrhagic Stroke, Thrombocytopenia

Adverse event resulted in: death, hospitalization

Drug(s) suspected as cause:
Rituximab
    Dosage: unk, single
    Indication: Mantle Cell Lymphoma Recurrent
    Start date: 2005-07-29
    End date: 2005-07-29

Rituximab
    Dosage: unk, single
    Start date: 2005-07-01
    End date: 2005-07-01

Zevalin
    Dosage: 0.3 mci/kg, single
    Indication: Mantle Cell Lymphoma Recurrent
    Start date: 2005-07-29
    End date: 2005-07-29

Other drugs received by patient: Fludara



Possible Zevalin side effects in

Reported by a physician from United States on 2012-08-09

Patient:

Reactions: Encephalopathy

Adverse event resulted in: death

Drug(s) suspected as cause:
Zevalin
    Dosage: unk
    Indication: Product Used FOR Unknown Indication

Hematopoetic Progenitor Cells Human
    Dosage: unk
    Indication: Product Used FOR Unknown Indication

Multi-Agent Chemotherapy
    Dosage: unk
    Indication: Product Used FOR Unknown Indication



Possible Zevalin side effects in 60 year old male

Reported by a health professional (non-physician/pharmacist) from United States on 2012-08-07

Patient: 60 year old male, weighing 107.0 kg (235.4 pounds)

Reactions: Myoclonus

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
Zevalin
    Dosage: 30.4 mci/x 1/iv
    Indication: Multiple Myeloma
    Start date: 2012-06-06

Zevalin
    Dosage: 5.493 micocuries/x 1/iv
    Indication: Multiple Myeloma
    Start date: 2012-05-30

Other drugs received by patient: Potassium Phosphates; Melphalan Hydrochloride; Gabapentin; Crestor; Aspirin; Dexamethasone; Metoprolol Tartrate; Ondansetron; Acid Prestudy; K-Phos Premix; Isosorbide; Levothyroxine Sodium; MAG Sulfur; Nifedipine; Lasix; Protonix; Nahco3



Possible Zevalin side effects in male

Reported by a health professional (non-physician/pharmacist) from Italy on 2012-07-30

Patient: male

Reactions: Myelodysplastic Syndrome, Azotaemia

Adverse event resulted in: death

Drug(s) suspected as cause:
Doxorubicin Hydrochloride
    Dosage: 380 mg
    Indication: Diffuse Large B-Cell Lymphoma
    Start date: 2007-03-13
    End date: 2007-05-17

Zevalin
    Dosage: 1.6 mg
    Indication: Diffuse Large B-Cell Lymphoma
    Start date: 2007-07-19
    End date: 2007-07-19

Vincristine
    Dosage: 8 mg
    Indication: Diffuse Large B-Cell Lymphoma
    Start date: 2007-03-13
    End date: 2007-05-17

Cyclophosphamide
    Dosage: 5700 mg
    Indication: Diffuse Large B-Cell Lymphoma
    Start date: 2007-03-13
    End date: 2007-05-17



Possible Zevalin side effects in 76 year old male

Reported by a physician from Italy on 2012-07-30

Patient: 76 year old male

Reactions: Neoplasm Malignant, Myelodysplastic Syndrome

Adverse event resulted in: death

Drug(s) suspected as cause:
Doxorubicin HCL
    Dosage: 380 mg, cyclic
    Indication: B-Cell Lymphoma
    Start date: 2007-03-13
    End date: 2007-05-17

Vincristine Sulfate
    Dosage: 8 mg, cyclic
    Indication: B-Cell Lymphoma
    Start date: 2007-03-13
    End date: 2007-05-17

Cyclophosphamide
    Dosage: 5700 mg, cyclic
    Indication: B-Cell Lymphoma
    Start date: 2007-03-13
    End date: 2007-05-17

Zevalin
    Dosage: 1.6 mg, total
    Indication: Diffuse Large B-Cell Lymphoma
    Start date: 2007-07-19
    End date: 2007-07-19



Possible Zevalin side effects in

Reported by a consumer/non-health professional from Germany on 2012-07-13

Patient:

Reactions: White Blood Cell Count Decreased, Pancreatic Carcinoma, Platelet Count Decreased, Neutrophil Count Decreased

Adverse event resulted in: death

Drug(s) suspected as cause:
Zevalin
    Dosage: unk, single
    Indication: Lymphoma
    Start date: 2010-12-14
    End date: 2010-12-14

Zevalin
    Dosage: unk, single
    Start date: 2010-12-07
    End date: 2010-12-07



Possible Zevalin side effects in male

Reported by a health professional (non-physician/pharmacist) from United States on 2012-07-10

Patient: male, weighing 48.5 kg (106.8 pounds)

Reactions: Myoclonus

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
Zevalin
    Dosage: 30.4 mci, single
    Indication: Multiple Myeloma
    Start date: 2012-06-06
    End date: 2012-06-06

Zevalin
    Dosage: 5.493 mci, single
    Start date: 2012-05-30
    End date: 2012-05-30

Rituxan
    Dosage: 220 mg, single
    Indication: Multiple Myeloma
    Start date: 2012-06-06
    End date: 2012-06-06

Rituxan
    Dosage: 220 mg, single
    Start date: 2012-05-30
    End date: 2012-05-30

Other drugs received by patient: Folic Acid; Dexamethasone; Metoprolol; K-Phos Premix; Lasix; Magnesium Sulfate; Sodium Bicarbonate; Aspirin; Gabapentin; Nifedipine; Crestor; Ondansetron; Protonix; Melphalan Hydrochloride; Isosorbide Mononitrate; K-Phos Neutral; Levothyroxine Sodium



Possible Zevalin side effects in

Reported by a consumer/non-health professional from Germany on 2012-06-21

Patient:

Reactions: Sepsis, Progressive Multifocal Leukoencephalopathy, Meningitis Tuberculous

Adverse event resulted in: death

Drug(s) suspected as cause:
Cisplatin
    Dosage: unk
    Indication: Product Used FOR Unknown Indication

Neupogen
    Dosage: unk
    Indication: Product Used FOR Unknown Indication

Rituxan
    Dosage: unk
    Indication: Product Used FOR Unknown Indication

Cyclophosphamide
    Dosage: 2000 mg/m2, unk
    Indication: Product Used FOR Unknown Indication

Carboplatin
    Dosage: unk
    Indication: Product Used FOR Unknown Indication

Etoposide
    Dosage: unk
    Indication: Product Used FOR Unknown Indication

Zevalin
    Dosage: unk
    Indication: Product Used FOR Unknown Indication

Prednisone TAB
    Dosage: unk
    Indication: Product Used FOR Unknown Indication

Busulfan
    Dosage: 12 mg/kg, unk
    Indication: Product Used FOR Unknown Indication

Fludara
    Dosage: 250 mg/m2, unk
    Indication: Product Used FOR Unknown Indication

Doxorubicin Hydrochloride
    Dosage: unk
    Indication: Product Used FOR Unknown Indication

Ifosfamide
    Dosage: unk
    Indication: Product Used FOR Unknown Indication

Vincristine Sulfate
    Dosage: unk
    Indication: Product Used FOR Unknown Indication



Possible Zevalin side effects in

Reported by a consumer/non-health professional from Germany on 2012-06-14

Patient:

Reactions: Cervix Carcinoma Stage I, Platelet Count Decreased, Pyrexia, Neutrophil Count Decreased

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
Zevalin
    Dosage: 130 mbq, single
    Start date: 2009-11-17
    End date: 2009-11-17

Rituxan
    Dosage: 400 mg, single
    Start date: 2009-11-17
    End date: 2009-11-17

Rituxan
    Dosage: 400 mg, single
    Indication: Follicle Centre Lymphoma, Follicular Grade I, II, III Stage I
    Start date: 2009-11-24
    End date: 2009-11-24

Zevalin
    Dosage: 898 mbq, single
    Indication: Follicle Centre Lymphoma, Follicular Grade I, II, III Stage I
    Start date: 2009-11-24
    End date: 2009-11-24

Other drugs received by patient: Isodine; Pyrinazin; Levofloxacin; PL Gran.; BIO Three / 01068501 /; Amlodipine; Restamin; Pursennid / 00571901 /; SP / 00312001 /



Possible Zevalin side effects in

Reported by a consumer/non-health professional from Canada on 2012-06-13

Patient:

Reactions: Sepsis, Progressive Multifocal Leukoencephalopathy, Meningitis Tuberculous

Adverse event resulted in: death

Drug(s) suspected as cause:
Neupogen
    Dosage: unk
    Indication: Product Used FOR Unknown Indication

Rituxan
    Dosage: unk
    Indication: Product Used FOR Unknown Indication

Busulfan
    Dosage: 12 mg/kg, qd
    Indication: Product Used FOR Unknown Indication

Cisplatin
    Dosage: unk
    Indication: Product Used FOR Unknown Indication

Cyclophosphamide
    Dosage: 2000 mg/m2, qd
    Indication: Product Used FOR Unknown Indication

Etoposide
    Dosage: unk
    Indication: Product Used FOR Unknown Indication

Ifosfamide
    Dosage: unk
    Indication: Product Used FOR Unknown Indication

Zevalin
    Dosage: unk
    Indication: Product Used FOR Unknown Indication

Prednisone TAB
    Dosage: unk
    Indication: Product Used FOR Unknown Indication

Vincristine Sulfate
    Dosage: unk
    Indication: Product Used FOR Unknown Indication

Fludara
    Dosage: 250 mg/m2, qd
    Indication: Product Used FOR Unknown Indication

Doxorubicin Hydrochloride
    Dosage: unk
    Indication: Product Used FOR Unknown Indication

Carboplatin
    Dosage: unk
    Indication: Product Used FOR Unknown Indication



Possible Zevalin side effects in

Reported by a consumer/non-health professional from Germany on 2012-06-01

Patient:

Reactions: Cardiomyopathy

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
Zevalin

Other drugs received by patient: Crestor



Possible Zevalin side effects in 36 year old female

Reported by a physician from Korea, Republic of on 2012-05-24

Patient: 36 year old female

Reactions: Multi-Organ Failure, Interstitial Lung Disease, Acute Respiratory Distress Syndrome

Adverse event resulted in: death, hospitalization

Drug(s) suspected as cause:
Zevalin
    Dosage: 0.4 mci/kg
    Indication: Diffuse Large B-Cell Lymphoma
    Start date: 2005-10-01
    End date: 2005-10-01

Rituximab
    Indication: Diffuse Large B-Cell Lymphoma
    Start date: 2005-10-01
    End date: 2005-10-01



Possible Zevalin side effects in

Reported by a physician from Germany on 2012-05-18

Patient:

Reactions: Prostate Cancer

Drug(s) suspected as cause:
Zevalin
    Dosage: unk
    Indication: Product Used FOR Unknown Indication
    Start date: 2004-01-01
    End date: 2004-01-01

Oncovin
    Dosage: unk
    Indication: Product Used FOR Unknown Indication

Corticosteroid NOS
    Dosage: unk
    Indication: Product Used FOR Unknown Indication

Nitrogen Mustard
    Dosage: unk
    Indication: Product Used FOR Unknown Indication



Possible Zevalin side effects in

Reported by a consumer/non-health professional from Germany on 2012-05-18

Patient:

Reactions: Squamous Cell Carcinoma of Skin

Drug(s) suspected as cause:
Anthracycline
    Dosage: unk
    Indication: Product Used FOR Unknown Indication

Nitrogen Mustard
    Dosage: unk
    Indication: Product Used FOR Unknown Indication

Zevalin
    Dosage: unk
    Indication: Product Used FOR Unknown Indication
    Start date: 2004-01-01
    End date: 2004-01-01

Corticosteroid NOS
    Dosage: unk
    Indication: Product Used FOR Unknown Indication

Oncovin
    Dosage: unk
    Indication: Product Used FOR Unknown Indication



Possible Zevalin side effects in

Reported by a consumer/non-health professional from Germany on 2012-05-16

Patient:

Reactions: Ventricular Hypokinesia

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
Zevalin



Possible Zevalin side effects in male

Reported by a consumer/non-health professional from United States on 2012-05-04

Patient: male, weighing 104.3 kg (229.5 pounds)

Reactions: NO Adverse Event

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
Rituximab 375 MG / M2 Genentech
    Dosage: 810-840 mg 5 doses iv
    Start date: 2011-05-23
    End date: 2011-08-22

Zevalin
    Dosage: 31.5 mci once iv
    Indication: Lymphoma
    Start date: 2011-11-16



Possible Zevalin side effects in 55 year old male

Reported by a physician from United States on 2012-04-24

Patient: 55 year old male, weighing 92.0 kg (202.4 pounds)

Reactions: White Blood Cell Count Decreased, Febrile Neutropenia, Toxicity To Various Agents, Perirectal Abscess, Rash Macular, Haemoglobin Decreased, Stem Cell Transplant, Haematocrit Decreased, Catheter Site Erythema, Diarrhoea, Hypophagia, Catheter Site Related Reaction

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
Zevalin
    Dosage: 4.6 mci, single, intravenous (not otherwise specified)
    Indication: Multiple Myeloma
    Start date: 2011-05-03
    End date: 2011-05-03

Cefepime
    Dosage: 2 g, tid, intravenous (not otherwise specified)
    Indication: Pyrexia
    Start date: 2011-06-03
    End date: 2011-06-06

Rituxan
    Dosage: 200 mg, single
    Indication: Multiple Myeloma
    Start date: 2011-05-12
    End date: 2011-05-12

Meropenem
    Dosage: 1 g, qd, intravenous (not otherwise specified)
    Indication: Pyrexia
    Start date: 2011-06-06
    End date: 2011-06-18

Metronidazole
    Dosage: 500 mg, tid, oral
    Administration route: Oral
    Indication: Prophylaxis
    Start date: 2011-06-04
    End date: 2011-06-05

Other drugs received by patient: (Famvir / 01226201 / ); Ativan; Allopurinol; Colchicine; Neurontin; Dilaudid; Seroquel; Aspirin; Fentanyl Citrate; Atenolol



Possible Zevalin side effects in

Reported by a consumer/non-health professional from United States on 2012-04-24

Patient:

Reactions: White Blood Cell Count Decreased, Diarrhoea, Hypophagia, Febrile Neutropenia, Perirectal Abscess, Rash Macular

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
Metronidazole
    Dosage: unk, unknown

Zevalin
    Dosage: 4.6 mci, single
    Start date: 2011-05-03
    End date: 2011-05-03

Metronidazole
    Dosage: 500 mg, tid
    Administration route: Oral
    Indication: Pyrexia
    Start date: 2011-06-04
    End date: 2011-06-05

Zevalin
    Dosage: 31.6 mci, single
    Indication: Multiple Myeloma
    Start date: 2011-05-12
    End date: 2011-05-12

Meropenem
    Dosage: 1 g, qd
    Indication: Pyrexia
    Start date: 2011-06-06
    End date: 2011-06-18

Rituxan
    Dosage: 200 mg, single
    Indication: Multiple Myeloma
    Start date: 2011-05-03
    End date: 2011-05-03

Rituxan
    Dosage: 200 mg, single
    Start date: 2011-05-12
    End date: 2011-05-12

Cefepime
    Dosage: 2 g, tid
    Indication: Pyrexia
    Start date: 2011-06-03
    End date: 2011-06-06

Other drugs received by patient: Atenolol; Neupogen; Fentanyl; Allopurinol; Colchicine; Aspirin; Famvir / 01226201 /; Seroquel; Dilaudid; Vancomycin; Neurontin; Vancomycin; Aztreonam; Ciprofloxacin; Ativan



Possible Zevalin side effects in

Reported by a consumer/non-health professional from Germany on 2012-04-20

Patient:

Reactions: Delayed Engraftment, Cytomegalovirus Viraemia, Hepatic Failure

Adverse event resulted in: death

Drug(s) suspected as cause:
Rituximab
    Dosage: 250 mg/m2, single, on day -22
    Indication: Multiple Myeloma

Autologous Stem Cell Transplant
    Dosage: at least 2 x 10(6) cd34/kg stem cells, on day 0
    Indication: Multiple Myeloma

Rituximab
    Dosage: 250 mg/m2, single, on day -14
    Indication: Surgical Preconditioning

Zevalin
    Dosage: unk, on day -22
    Indication: Multiple Myeloma

Melphalan Hydrochloride
    Indication: Multiple Myeloma

Zevalin
    Dosage: 16 gy, single, on day -14
    Indication: Surgical Preconditioning

Melphalan Hydrochloride
    Dosage: 100 mg/m2, qd, on days -2 and -1
    Indication: Surgical Preconditioning

Other drugs received by patient: Sargramostim



Possible Zevalin side effects in 79 year old male

Reported by a physician from Japan on 2012-04-20

Patient: 79 year old male, weighing 66.0 kg (145.2 pounds)

Reactions: Blood Urea Increased, C-Reactive Protein Increased, Pancytopenia, Mantle Cell Lymphoma Recurrent

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
Zevalin
    Dosage: 974 mbq, single, intravenous, 130 mbq, single, intravenous
    Indication: Mantle Cell Lymphoma Stage I
    Start date: 2009-01-27
    End date: 2009-01-27

Zevalin

Rituxan
    Dosage: unk, unk
    Indication: Mantle Cell Lymphoma Stage I
    Start date: 2009-01-27
    End date: 2009-01-27

Rituxan
    Dosage: unk, unk
    Indication: Mantle Cell Lymphoma Stage I
    Start date: 2009-01-20
    End date: 2009-01-20

Other drugs received by patient: Allegra (Fexofenadine) Tablet; Coniel (Benidipine Hydrochloride) Tablet; Other Analgesics and Antipyretics (Other Analgesics and Antipyretics); Doxazosin Mesylate; Urinorm (Benzbromarone) Tablet; Antihistamines (Antihistamines); Valtrex; Maglax (Magnesium Oxide) Tablet



Possible Zevalin side effects in

Reported by a physician from Germany on 2012-04-20

Patient:

Reactions: Gastrointestinal Necrosis

Adverse event resulted in: death

Drug(s) suspected as cause:
Melphalan Hydrochloride
    Dosage: 100 mg/m2, qd, on days -2 and -1
    Indication: Surgical Preconditioning

Rituximab
    Dosage: 250 mg/m2, single, on day -22
    Indication: Multiple Myeloma

Rituximab
    Dosage: 250 mg/m2, single, on day -14
    Indication: Surgical Preconditioning

Melphalan Hydrochloride
    Indication: Multiple Myeloma

Autologous Stem Cell Transplant
    Dosage: at least 2 x 10(6) cd34/kg stem cells, on day 0
    Indication: Multiple Myeloma

Zevalin
    Dosage: 20 gy, single, on day -14
    Indication: Surgical Preconditioning

Zevalin
    Dosage: unk, on day -22
    Indication: Multiple Myeloma

Other drugs received by patient: Leukine



Possible Zevalin side effects in

Reported by a physician from Germany on 2012-04-20

Patient:

Reactions: Venoocclusive Disease

Adverse event resulted in: death

Drug(s) suspected as cause:
Melphalan Hydrochloride
    Indication: Multiple Myeloma

Rituximab
    Dosage: 250 mg/m2, single, on day -14
    Indication: Surgical Preconditioning

Melphalan Hydrochloride
    Dosage: 100 mg/m2, qd, on days -2 and -1
    Indication: Surgical Preconditioning

Zevalin
    Dosage: 20 gy, single, on day -14
    Indication: Surgical Preconditioning

Rituximab
    Dosage: 250 mg/m2, single, on day -22
    Indication: Multiple Myeloma

Autologous Stem Cell Transplant
    Dosage: at least 2 x 10(6) cd34/kg stem cells, on day 0
    Indication: Multiple Myeloma

Zevalin
    Dosage: unk, on day -22
    Indication: Multiple Myeloma

Other drugs received by patient: Leukine



Possible Zevalin side effects in male

Reported by a consumer/non-health professional from United States on 2012-04-19

Patient: male, weighing 92.0 kg (202.4 pounds)

Reactions: Injection Site Erythema, Diarrhoea, Hypophagia, Febrile Neutropenia, Injection Site Warmth, Perirectal Abscess, Rash Macular

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
Metronidazole
    Dosage: 500 mg, tid
    Administration route: Oral
    Indication: Prophylaxis
    Start date: 2011-06-04
    End date: 2011-06-05

Meropenem
    Dosage: 1 g, qd
    Indication: Pyrexia
    Start date: 2011-06-06
    End date: 2011-06-18

Rituxan
    Dosage: 200 mg, once/single
    Indication: Multiple Myeloma
    Start date: 2011-05-12
    End date: 2011-05-12

Cefepime
    Dosage: 2 g, tid
    Indication: Pyrexia
    Start date: 2011-06-03
    End date: 2011-06-06

Zevalin
    Dosage: 31.6 mci, once/single
    Indication: Multiple Myeloma
    Start date: 2011-05-12
    End date: 2011-05-12

Zevalin
    Dosage: 4.6 mci, once/single
    Start date: 2011-05-03
    End date: 2011-05-03

Rituxan
    Dosage: 200 mg, once/single
    Start date: 2011-05-03
    End date: 2011-05-03

Other drugs received by patient: Seroquel; Colchicine; Neurontin; Neupogen; Famvir; Vancomycin; Micafungin; Aspirin; Melphalan Hydrochloride; Dilaudid; Fentanyl; Atenolol; Vancomycin; Allopurinol; Ativan



Possible Zevalin side effects in male

Reported by a consumer/non-health professional from United States on 2012-04-11

Patient: male, weighing 104.3 kg (229.5 pounds)

Reactions: Pneumonia, Fatigue, Nausea, Mental Status Changes, Pyrexia, Asthenia

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
Rituximab
    Dosage: 810-840 mg 5 doses iv
    Start date: 2011-05-23
    End date: 2011-08-22

Zevalin
    Dosage: 31.5 mci once iv
    Indication: Lymphoma
    Start date: 2011-11-16



Possible Zevalin side effects in 55 year old male

Reported by a physician from Japan on 2012-03-23

Patient: 55 year old male, weighing 65.2 kg (143.4 pounds)

Reactions: Extranodal Marginal Zone B-Cell Lymphoma (Malt Type) Recurrent, Adenovirus Infection, Cystitis Haemorrhagic

Adverse event resulted in: death, hospitalization

Drug(s) suspected as cause:
Rituximab (Rituximab)
    Dosage: 250 mg/m2, single, iv drip, 250 mg/m2, single, iv drip
    Indication: Extranodal Marginal Zone B-Cell Lymphoma (Malt Type) Stage III
    Start date: 2009-08-19
    End date: 2009-08-19

Rituximab (Rituximab)
    Dosage: 250 mg/m2, single, iv drip, 250 mg/m2, single, iv drip
    Indication: Extranodal Marginal Zone B-Cell Lymphoma (Malt Type) Stage III
    Start date: 2009-08-26
    End date: 2009-08-26

Zevalin
    Dosage: 130 mbq, single, intravenous
    Indication: Extranodal Marginal Zone B-Cell Lymphoma (Malt Type) Stage III
    Start date: 2009-08-19
    End date: 2009-08-19

Zevalin
    Dosage: 965 mbq, single, intravenous;
    Indication: Extranodal Marginal Zone B-Cell Lymphoma (Malt Type) Stage III
    Start date: 2009-08-26
    End date: 2009-08-26

Fludara
    Dosage: intravenous
    Indication: Extranodal Marginal Zone B-Cell Lymphoma (Malt Type) Stage III
    Start date: 2009-03-26
    End date: 2009-06-05

Other drugs received by patient: Other Analgesics and Antipyretics (Other Analgesics and Antipyrectics); Antihistamines; Other Analgesics and Antipyretics (Other Analgesics and Antipyrectics); Antihistamines



Possible Zevalin side effects in

Reported by a health professional (non-physician/pharmacist) from United States on 2012-03-14

Patient:

Reactions: Blood Lactate Dehydrogenase Increased, Anaemia, Leukaemoid Reaction, Post Herpetic Neuralgia, Mental Status Changes, Anaemia Macrocytic, Chronic Myeloid Leukaemia, Superinfection Viral, Herpes Zoster, Hypokalaemia, Glycosylated Haemoglobin Increased, Rash Erythematous, Chest Pain, Platelet Count Decreased, Leukocytosis, Blood Glucose Increased

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
Rituximab
    Dosage: 480 mg, single
    Indication: B-Cell Lymphoma
    Start date: 2011-03-17
    End date: 2011-03-17

Zevalin
    Dosage: 6.1 mci, single
    Start date: 2011-03-09
    End date: 2011-03-09

Rituximab
    Dosage: 480 mg, single
    Start date: 2011-03-09
    End date: 2011-03-09

Zevalin
    Dosage: 32 mci, single
    Indication: B-Cell Lymphoma
    Start date: 2011-03-17
    End date: 2011-03-17

Bendamustine
    Dosage: 168 to 175 mg, unk
    Start date: 2010-10-21
    End date: 2010-10-21

Rituximab
    Dosage: unk
    Start date: 2010-11-23
    End date: 2010-11-23

Rituximab
    Dosage: unk
    Start date: 2010-10-21
    End date: 2010-10-21

Bendamustine
    Dosage: 168 to 175 mg, unk
    Start date: 2010-12-23
    End date: 2010-12-23

Bendamustine
    Dosage: 168 to 175 mg, unk
    Start date: 2010-11-23
    End date: 2010-11-23

Rituximab
    Dosage: unk
    Start date: 2011-01-20
    End date: 2011-01-20

Rituximab
    Dosage: unk
    Start date: 2010-12-23
    End date: 2010-12-23

Bendamustine
    Dosage: 168 to 175 mg, unk
    Indication: B-Cell Lymphoma
    Start date: 2011-01-20
    End date: 2011-01-20

Other drugs received by patient: Colace; Zoloft; Metaglip; Vicodin; Glucotrol; Mobic; Glucophage; Novolog; Januvia; Aricept



Possible Zevalin side effects in 42 year old female

Reported by a consumer/non-health professional from United States on 2012-03-09

Patient: 42 year old female, weighing 140.0 kg (308.0 pounds)

Reactions: Aplastic Anaemia, Pancytopenia, Febrile Neutropenia, Emotional Disorder

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
Zevalin
    Dosage: 1df=0.4mcl/kg also 5.8mcl (17aug11-24aug2011).
    Indication: Lymphoma
    Start date: 2011-08-17
    End date: 2011-08-24

Abilify
    Dosage: also 2mg
    Administration route: Oral

Rituximab
    Dosage: 24aug11-24aug11 17aug11:500mg/m2 8jul11:750mg/m2 apr11-unk:375mg/m2
    Indication: Lymphoma
    Start date: 2011-08-17
    End date: 2011-08-24

Other drugs received by patient: Zyrtec; Vitamin B6; Trileptal; Acetaminophen; Calcium; Zoloft; Fish OIL; Vitamin D; Diphenhydramine HCL; Trazodone HCL; Coumadin; Multi-Vitamin



Possible Zevalin side effects in 36 year old female

Reported by a individual with unspecified qualification from Korea, Republic of on 2012-03-08

Patient: 36 year old female

Reactions: Multi-Organ Failure, Interstitial Lung Disease, Acute Respiratory Distress Syndrome

Adverse event resulted in: death, hospitalization

Drug(s) suspected as cause:
Rituximab
    Indication: Diffuse Large B-Cell Lymphoma
    Start date: 2005-10-01
    End date: 2005-10-01

Zevalin
    Dosage: 0.4 mci/kg
    Indication: Diffuse Large B-Cell Lymphoma
    Start date: 2005-10-01
    End date: 2005-10-01



Possible Zevalin side effects in female

Reported by a consumer/non-health professional from United States on 2012-03-02

Patient: female, weighing 80.6 kg (177.3 pounds)

Reactions: Blood Lactate Dehydrogenase Increased, Leukocytosis, Herpes Zoster, Chronic Myeloid Leukaemia

Drug(s) suspected as cause:
Zevalin
    Dosage: 32 mci once iv
    Start date: 2011-03-17

Bendamustine 90 MG / M2 Cephalon
    Dosage: 168-175 mg 2 days per cycle iv
    Indication: B-Cell Lymphoma
    Start date: 2010-10-28
    End date: 2011-01-21



Possible Zevalin side effects in

Reported by a health professional (non-physician/pharmacist) from United States on 2012-02-29

Patient:

Reactions: Blood Lactate Dehydrogenase Increased, Anaemia, Post Herpetic Neuralgia, Leukaemoid Reaction, Mental Status Changes, Anaemia Macrocytic, Chronic Myeloid Leukaemia, Herpes Zoster, Superinfection Viral, Hypokalaemia, Glycosylated Haemoglobin Increased, Rash Erythematous, Chest Pain, Platelet Count Decreased, Leukocytosis, Blood Glucose Increased

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
Zevalin
    Dosage: 32 mci, single
    Indication: B-Cell Lymphoma
    Start date: 2011-03-17
    End date: 2011-03-17

Rituximab
    Dosage: 480 mg, single
    Start date: 2011-03-09
    End date: 2011-03-09

Bendamustine
    Dosage: 168 to 175 mg, unk
    Start date: 2010-12-23
    End date: 2010-12-23

Bendamustine
    Dosage: 168 to 175 mg, unk
    Start date: 2010-11-23
    End date: 2010-11-23

Rituximab
    Dosage: unk
    Start date: 2010-12-23
    End date: 2010-12-23

Bendamustine
    Dosage: 168 to 175 mg, unk
    Start date: 2010-10-21
    End date: 2010-10-21

Zevalin
    Dosage: 6.1 mci, single
    Start date: 2011-03-09
    End date: 2011-03-09

Rituximab
    Dosage: unk
    Start date: 2011-01-20
    End date: 2011-01-20

Rituximab
    Dosage: unk
    Start date: 2010-11-23
    End date: 2010-11-23

Bendamustine
    Dosage: 168 to 175 mg, unk
    Indication: B-Cell Lymphoma
    Start date: 2011-01-20
    End date: 2011-01-20

Rituximab
    Dosage: 480 mg, single
    Indication: B-Cell Lymphoma
    Start date: 2011-03-17
    End date: 2011-03-17

Rituximab
    Dosage: unk
    Start date: 2010-10-21
    End date: 2010-10-21

Other drugs received by patient: Colace; Glucophage; Metaglip; Mobic; Vicodin; Novolog; Zoloft; Januvia; Aricept; Glucotrol

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2014